Genetic Testing Resources

This page includes draft policy information that is still in development. You are welcome to use these materials, but please keep in mind that they may be incomplete or subject to change.

We welcome suggestions and additional resources. To share materials or feedback, please contact anna@statezebranetwork.org

Genetic Testing

Genetic testing analyzes DNA to identify disease-related variants. It is valued for enabling earlier diagnosis, more precise care, and better access to lifesaving treatments.

Party Pro / Cons and Concerns

Important Note: Remember, there are nuances that differentiate in each state. This material provides general information that can be adapted to truly align to your own state.

Democrat Party Pros

Arguments Supporting Genetic Testing Policies

Democrat Party Pros

• Earlier diagnosis through genetic testing helps reduce diagnostic delays (“diagnostic odyssey”) for rare disease patients. • Supports policies that expand insurance coverage, newborn screening add-ons, and access to advanced testing (ex ome/genome). • Promotes equity by ensuring underserved populations have access to rare disease diagnostics.

Democrat Party Cons/Concerns

Arguments Raising Caution for Rare Disease Patients)

Democrat Party Cons/Concerns

• Strong concerns about privacy, data security, and potential misuse of genetic information. • Cost concerns for states or Medicaid programs when broad genomic testing is mandated. • Worries that testing access without guaranteed follow-up care or coverage can worsen inequities.

Republican Party Pros

Arguments Supporting Genetic Testing Policies

Republican Party Pros

• Supports patient choice and access to innovative genetic technologies that help families make informed decisions. • Early diagnosis aligns with pro-family approaches and can reduce long-term healthcare spending for rare conditions. • Favorable to state flexibility for implementing genetic testing programs.

Republican Party Cons/Concerns

Arguments Raising Caution for Rare Disease Patients)

Republican Party Cons/Concerns

• Concern about government mandates requiring broad coverage of expensive genomic tests. • Skepticism toward centralized genetic data collection or government-held genetic databases. • Potential cost impacts on private insurance markets and state budgets for high-cost testing.

From the Patient Perspective

Genetic testing is essential because it can finally provide answers, shorten years of misdiagnosis, and guide access to the right treatments for rare diseases. Families value how testing can confirm a diagnosis, connect them to specialists, and open doors to clinical trials or targeted therapies. At the same time, patients worry about whether testing will be covered by insurance, how long results will take, and whether they’ll be able to get the follow-up care they need. Privacy and the handling of genetic data also remain major concerns for many families.

Talking Points Expand Access to Genetic Testing and Early Diagnosis

Guarantee insurance and Medicaid coverage for genetic testing.
Reduce prior authorization delays that prolong the diagnostic odyssey.
Ensure access to genetic counseling and rare-disease specialists.
Protect privacy and data security amid evolving federal rules.
Support cascade testing when clinically appropriate for families.

Policy Guidelines

Expand equitable access to diagnostic genetic testing.
Policies should ensure that all patients—regardless of income, geography, or insurance type—can access appropriate genetic tests, including panels, exome, or genome sequencing when medically indicated.

Require timely insurance coverage with minimal barriers.
Both Medicaid and private insurers should cover medically necessary genetic testing without unnecessary prior authorization delays, step requirements, or restrictive criteria that hinder diagnosis for rare diseases.

Support access to follow-up care and genetic counseling.
Testing must be paired with coverage and reimbursement for genetic counseling, confirmatory diagnostics, and specialist care to ensure patients can understand their results and receive appropriate treatment.

Promote the responsible integration of advanced technologies.
Policies should enable the use of updated testing methods—like whole-genome sequencing—in specific clinical situations while balancing feasibility, evidence, and ethical considerations.

Strengthen privacy and data protection.
Clear standards should govern how genetic information is stored, shared, and used. Policies must protect patients from misuse, discrimination, or unauthorized access to their genetic data.

Support provider and lab workforce development.
Increase training and capacity for genetic counselors, clinical geneticists, lab personnel, and primary care providers who guide patients through testing and rare disease diagnosis.

Improve transparency and reduce administrative burden.
Insurers should provide clear, consistent criteria for coverage and reimbursement decisions, and states should monitor denials and delays to ensure testing access is fair and efficient.

Invest in early diagnosis and research.
Policies should support research, pilot programs, and partnerships that improve early detection of rare diseases, including integration with newborn screening where appropriate.

Encourage family-based testing when clinically justified.
Coverage policies should include cascade testing for family members when it informs diagnosis, treatment, or prevention of rare genetic conditions.

Prioritize patient voice and lived experience in policymaking.
Patients and advocates should be included in policy design, advisory groups, and implementation processes to ensure that testing policies reflect real-world needs.